We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sticking Points in Compounding Talks Reflect Long-Held FDA Frustrations
Sticking Points in Compounding Talks Reflect Long-Held FDA Frustrations
September 16, 2013
House and Senate aides negotiating compounding pharmacy legislation are quibbling over what volume of interstate commerce by compounders should trigger mandatory FDA oversight, and how that volume should be measured.